Primary progressive aphasia (PPA) is diagnosed when language impairment arises as the most salient symptom and progresses to affect daily functioning. Within the last few decades, it has become clear that AD does not exclusively manifest as an amnestic syndrome, and that, although less common than amnesia, progressive visuospatial, language (i.e., aphasic), or behavioral deficits may also appear early in disease course ( Dickerson et al., 2017 Rogalski et al., 2016). Studies have shown memory to be the first cognitive domain to decline in patients who progress to DAT ( Petersen et al., 2009) as such, research on screening tools has typically focused on the amnestic phenotype of dementia. In particular, individuals with mild cognitive impairment (MCI) (a prodromal state in which there is cognitive impairment with minimal impact in activities of daily living Petersen et al., 2018) have become increasingly important to research as they are at high risk for progression to DAT ( Gauthier et al., 2006). Several screening instruments have been developed to identify differences between normal age-related changes in cognition and mild stages of DAT. Dementia of the Alzheimer’s type (DAT) is typically characterized by episodic memory deficits, or amnesia, in early stages ( Weintraub, Wicklund, & Salmon, 2012). Alzheimer’s disease (AD) is the most common neurodegenerative disease causing dementia among individuals over 65 ( Hebert, Weuve, Scherr, & Evans, 2013). In primary care settings, screening tools for the early detection of cognitive impairment that are simple to administer, short, and well validated are particularly valuable. Early detection is critical for accurate and timely diagnosis and is important for facilitating entry into clinical trials, once available. Neurodegenerative disorders associated with aging are a rapidly growing public health crisis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |